1. jordanjames7
2. dlrothwell
3. wolvergeek
4. danielwilliamsms
5. 7946manley049
1.jordanjames7 01/26/2018
Crickets... Nobody?
2.7946manley049 01/29/2018
BMY Feb 62 calls are seeing interest with 6970 contracts trading
3.jordanjames7 01/22/2018
Product expansion
4.danielwilliamsms 06/04/2018
Announces results from Phase 3 CheckMate -227
5.wolvergeek 02/05/2018
Yes, by all means go down so I can buy more
6.dlrothwell 06/01/2018
Bristol-Myers Opdivo plus low-dose Vervoy
7.wolvergeek 04/17/2018
Bristol Myers Squibb (BMY) Will Face Significant Headwinds in 2019 - Here's Why
8.7946manley049 01/26/2018
$25 Million Payment
9.wolvergeek 04/17/2018
In CheckMate -141, Opdivo (nivolumab) Demonstrated Sustained Overall Survival (OS) Advantage over Standard of Care in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
10.jordanjames7 04/16/2018
Announces initial results from pivotal Phase 3 study (CheckMate -227) evaluating Opdivo 3 mg/kg plus low-dose…
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW